Clinical proteomics: A need to define the field and to begin to set adequate standards

作者：Harald Mischak, Rolf Apweiler, Rosamonde Elizabeth Banks, Mark R. Conaway, Joshua J. Coon, Anna F. Dominiczak, Jochen H. H. Ehrich, Danilo Fliser, Mark Girolami, Henning Hermjakob, Denis F. Hochstrasser, Joachim Jankowski, Bruce A. Julian, Walter Kölch, Ziad A. Massy, Neusuess Christian, Jan Novák, Karlheinz Peter, Kasper Rossing, Joost Peter Schanstra, O. John Semmes, Dan Theodorescu, Visith Thongboonkerd, Eva M. Weissinger, Jennifer E. Van Eyk, Tadashi Yamamoto · 发表于：PROTEOMICS - CLINICAL APPLICATIONS · 年份：2007 · DOI：10.1002/prca.200600771 · 被引用次数：307 · 研究领域：Advanced Proteomics Techniques and Applications、Advanced Biosensing Techniques and Applications、Metabolomics and Mass Spectrometry Studies

The aim of this manuscript is to initiate a constructive discussion about the definition of clinical proteomics, study requirements, pitfalls and (potential) use. Furthermore, we hope to stimulate proposals for the optimal use of future opportunities and seek unification of the approaches in clinical proteomic studies. We have outlined our collective views about the basic principles that should be considered in clinical proteomic studies, including sample selection, choice of technology and appropriate quality control, and the need for collaborative interdisciplinary efforts involving clinicians and scientists. Furthermore, we propose guidelines for the critical aspects that should be included in published reports. Our hope is that, as a result of stimulating discussion, a consensus will be reached amongst the scientific community leading to guidelines for the studies, similar to those already published for mass spectrometric sequencing data. We contend that clinical proteomics is not just a collection of studies dealing with analysis of clinical samples. Rather, the essence of clinical proteomics should be to address clinically relevant questions and to improve the state-of-the-art, both in diagnosis and in therapy of diseases.